$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000119312515371270 Filed on November 09, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$2.092M	$2.045M	$1.765M
YoY Change	4.98%	15.87%	-75.5%
Cost Of Revenue	$100.0K	$120.0K	$90.00K
YoY Change	11.11%	33.33%	80.0%
Gross Profit	$1.990M	$1.930M	$1.680M
YoY Change	4.74%	14.88%	-76.5%
Gross Profit Margin	95.12%	94.38%	95.19%
Selling, General & Admin	$2.940M	$2.770M	$2.720M
YoY Change	-3.92%	1.84%	-4.56%
% of Gross Profit	147.74%	143.52%	161.9%
Research & Development	$12.29M	$4.001M	$3.705M
YoY Change	236.71%	7.98%	-11.16%
% of Gross Profit	617.59%	207.31%	220.56%
Depreciation & Amortization	$40.00K	$40.00K	$40.00K
YoY Change	-20.0%	0.0%	33.33%
% of Gross Profit	2.01%	2.07%	2.38%
Operating Expenses	$15.24M	$4.001M	$3.705M
YoY Change	127.12%	7.98%	-11.16%
Operating Profit	-$13.25M	-$4.844M	-$4.753M
YoY Change	175.32%	1.91%	-3745.86%
Interest Expense	-$760.0K	$827.0K	$933.9K
YoY Change	-13.64%	-11.45%	-3.18%
% of Operating Profit
Other Income/Expense, Net	$550.0K	-$699.0K	-$827.1K
YoY Change		-15.49%	-58.61%
Pretax Income	-$13.46M	-$5.540M	-$5.580M
YoY Change	136.56%	-0.72%	198.4%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$13.46M	-$5.543M	-$5.580M
YoY Change	136.62%	-0.67%	198.75%
Net Earnings / Revenue	-643.45%	-271.05%	-316.18%
Basic Earnings Per Share
Diluted Earnings Per Share	-$523.5K	-$215.7K	-$324.4K
COMMON SHARES
Basic Shares Outstanding	128.4M shares	129.6M shares	86.00M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$82.20M	$93.50M	$54.60M
YoY Change	65.06%	71.25%	-13.61%
Cash & Equivalents	$33.09M	$28.66M	$7.933M
Short-Term Investments	$49.10M	$64.80M	$46.70M
Other Short-Term Assets	$1.200M	$800.0K	$700.0K
YoY Change	140.0%	14.29%	40.0%
Inventory
Prepaid Expenses
Receivables	$2.106M	$2.318M	$1.839M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$85.50M	$96.61M	$57.11M
YoY Change	63.75%	69.17%	-12.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$278.0K	$315.5K	$407.4K
YoY Change	-31.82%	-22.56%	-12.86%
Goodwill	$8.982M	$8.982M	$8.982M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$1.500M
YoY Change	-100.0%	-100.0%	-61.54%
Other Assets	$51.00K	$56.03K	$77.56K
YoY Change	-24.49%	-27.76%	-33.66%
Total Long-Term Assets	$9.464M	$9.506M	$11.10M
YoY Change	-8.99%	-14.37%	-18.7%
TOTAL ASSETS
Total Short-Term Assets	$85.50M	$96.61M	$57.11M
Total Long-Term Assets	$9.464M	$9.506M	$11.10M
Total Assets	$94.97M	$106.1M	$68.21M
YoY Change	51.67%	55.57%	-13.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.217M	$2.569M	$2.371M
YoY Change	79.51%	8.34%	3.52%
Accrued Expenses	$1.934M	$1.874M	$1.942M
YoY Change	-3.67%	-3.5%	-1.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.607M	$4.860M	$5.522M
YoY Change	-19.32%	-11.97%	280.81%
Total Short-Term Liabilities	$10.76M	$9.303M	$9.835M
YoY Change	6.87%	-5.4%	72.01%
LONG-TERM LIABILITIES
Long-Term Debt	$19.56M	$20.67M	$23.54M
YoY Change	-13.42%	-12.2%	-19.19%
Other Long-Term Liabilities	$139.0K	$148.7K	$187.4K
YoY Change	-20.12%	-20.64%	-5.3%
Total Long-Term Liabilities	$19.70M	$20.82M	$23.73M
YoY Change	-13.47%	-12.27%	-19.1%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.76M	$9.303M	$9.835M
Total Long-Term Liabilities	$19.70M	$20.82M	$23.73M
Total Liabilities	$30.46M	$30.12M	$33.56M
YoY Change	-7.23%	-10.26%	-9.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$838.5M	-$825.1M	-$773.9M
YoY Change	7.57%	6.62%	2.28%
Common Stock	$904.5M	$902.5M	$872.3K
YoY Change	11.55%	103369.27%	2.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.524M	$1.524M	$1.524M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	1.223M shares	1.223M shares	1.223M shares
Shareholders Equity	$64.51M	$75.99M	$34.65M
YoY Change
Total Liabilities & Shareholders Equity	$94.97M	$106.1M	$68.21M
YoY Change	51.67%	55.57%	-13.16%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$13.46M	-$5.543M	-$5.580M
YoY Change	136.62%	-0.67%	198.75%
Depreciation, Depletion And Amortization	$40.00K	$40.00K	$40.00K
YoY Change	-20.0%	0.0%	33.33%
Cash From Operating Activities	-$10.86M	-$4.480M	-$2.080M
YoY Change	131.56%	115.38%	-870.37%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$40.00K	-$10.00K
YoY Change	-100.0%	300.0%	-90.0%
Acquisitions
YoY Change
Other Investing Activities	$15.66M	$2.800M	$690.0K
YoY Change	196.59%	305.8%	-111.58%
Cash From Investing Activities	$15.66M	$2.760M	$680.0K
YoY Change	198.29%	305.88%	-111.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-370.0K	-1.110M	-820.0K
YoY Change	-50.0%	35.37%	-108.35%
NET CHANGE
Cash From Operating Activities	-10.86M	-4.480M	-2.080M
Cash From Investing Activities	15.66M	2.760M	680.0K
Cash From Financing Activities	-370.0K	-1.110M	-820.0K
Net Change In Cash	4.430M	-2.830M	-2.220M
YoY Change	-2561.11%	27.48%	-155.09%
FREE CASH FLOW
Cash From Operating Activities	-$10.86M	-$4.480M	-$2.080M
Capital Expenditures	$0.00	-$40.00K	-$10.00K
Free Cash Flow	-$10.86M	-$4.440M	-$2.070M
YoY Change	132.55%	114.49%	-659.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	128394655	shares
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7933470
CY2015Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	128394655	shares
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	129617501	shares
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	901242489
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	186670
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	75992814
CY2015Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20668112
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	148745
CY2015Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	3223151
CY2015Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	189875
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	50805
CY2015Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	4860418
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2568945
CY2015Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1213549
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1873842
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-825075335
CY2015Q3	us-gaap	Liabilities Liabilities	30120062
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	106112876
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	1296175
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q3	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9303205
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	53514
CY2015Q3	us-gaap	Interest Payable Current InterestPayableCurrent	283748
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2349000
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	56025
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	6540000
CY2015Q3	us-gaap	Assets Assets	106112876
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1174
CY2015Q3	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	152610
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2318202
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	315470
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	64811477
CY2015Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2015Q3	us-gaap	Assets Current AssetsCurrent	96606771
CY2015Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	64811477
CY2015Q3	us-gaap	Goodwill Goodwill	8982000
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	818176
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28658916
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2600000
CY2015Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	64761846
CY2015Q3	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2010Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1612322	shares
CY2010Q1	cris	Direct Offering Purchase Price DirectOfferingPurchasePrice	2.52
CY2010Q1	cris	Registered Direct Offering Number Of Warrant Per Unit RegisteredDirectOfferingNumberOfWarrantPerUnit	1
CY2010Q1	cris	Registered Direct Offering Number Of Common Stock Per Unit RegisteredDirectOfferingNumberOfCommonStockPerUnit	1
CY2010Q1	cris	Registered Direct Offering Units RegisteredDirectOfferingUnits	6449288	shares
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9591487
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1222846	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86030811	shares
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87253657	shares
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	810001410
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	212548
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	29783626
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	22589058
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	174018
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	122850
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4883
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	5709985
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2349183
CY2014Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1386226
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2007699
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-779555295
CY2014Q4	us-gaap	Liabilities Liabilities	32829943
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	62613569
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	872537
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure Nonrecurring LiabilitiesFairValueDisclosureNonrecurring	0
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10066867
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-10997
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	286075
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	67544
CY2014Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	13877
CY2014Q4	us-gaap	Assets Assets	62613569
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	15880
CY2014Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	152610
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1960995
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	407738
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	42791550
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1524029
CY2014Q4	us-gaap	Assets Current AssetsCurrent	52214909
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	42002782
CY2014Q4	us-gaap	Goodwill Goodwill	8982000
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	489844
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7747411
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	788768
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	42802547
CY2014Q4	us-gaap	Assets Fair Value Disclosure Nonrecurring AssetsFairValueDisclosureNonrecurring	0
CY2014Q4	cris	Stock Issued During Period Due To Exercise Of Warrants StockIssuedDuringPeriodDueToExerciseOfWarrants	238805	shares
CY2014Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.019	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.34
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400000	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.20
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.70	pure
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	640000	shares
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.021	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.65	pure
CY2010Q1	cris	Proceeds From Registered Direct Offering Of Common Stock And Warrants Net Of Issuance Costs ProceedsFromRegisteredDirectOfferingOfCommonStockAndWarrantsNetOfIssuanceCosts	14942000
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	25090908	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	64619407
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12120518
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12737636	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.71	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.79
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.022	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0185	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.70	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85962415	shares
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	65764
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	38284246
	us-gaap	Net Income Loss NetIncomeLoss	-13039864
	us-gaap	Revenues Revenues	7850782
	us-gaap	Repayments Of Debt RepaymentsOfDebt	813810
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	168343
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2213000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-11051161
	us-gaap	Licenses Revenue LicensesRevenue	3000000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1988703
	us-gaap	Interest Paid Capitalized InterestPaidCapitalized	713968
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-108511
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	362131
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1750
	us-gaap	Royalty Revenue RoyaltyRevenue	4895454
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13877
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13029416
	us-gaap	Investment Income Interest InvestmentIncomeInterest	129120
	us-gaap	Share Based Compensation ShareBasedCompensation	2245565
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-716786
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	256843
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	10180271
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1658017
	us-gaap	Interest Expense InterestExpense	2834609
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	11019468
	us-gaap	Costs And Expenses CostsAndExpenses	18901943
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-556967
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	1750
	us-gaap	Royalty Expense RoyaltyExpense	246280
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	345474
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	274661
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8475392
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	68716
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	105000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	919346
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	114058
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	49353851
	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	-91973
	cris	Research And Development Revenue Net ResearchAndDevelopmentRevenueNet	-44672
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b><u>Nature of Business</u></b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Curis, Inc. is a biotechnology company seeking to develop and commercialize innovative drug candidates for the treatment of human cancers. As used throughout these condensed consolidated financial statements, the term “the Company” refers to the business of Curis, Inc. and its wholly owned subsidiaries, except where the context otherwise requires, and the term “Curis” refers to Curis, Inc.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company conducts its research and development programs both internally and through strategic collaborations. The Company’s most advanced drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase, or HDAC, and phosphatidylinositol-3-kinase, or PI3K enzymes, that is being investigated in clinical studies in patients with lymphomas and solid tumors.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In January 2015, the Company entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets with Aurigene Discovery Technologies Limited, or Aurigene (see Note 4(b)). The collaboration is comprised of multiple programs, in which Curis has the option to exclusively license compounds once a development candidate is nominated within each respective program. In October 2015, the Company exercised options to license the first two programs under this collaboration. The first licensed program is focused on the development of orally-available small molecule antagonists of programmed death -1 (PD-1) and V-domain Ig suppressor of T cell activation (VISTA) in the immuno-oncology field. The Company has named CA-170, a PD-L1/VISTA antagonist, as the development candidate from this program. The second licensed program is focused on orally-available small molecule inhibitors of Interleukin-1 <font style="WHITE-SPACE: nowrap">receptor-associated</font> kinase 4 (IRAK4) in the precision oncology field. In addition, in October 2015 the Company selected a second preclinical program within the immuno-oncology part of the collaboration, the third overall collaboration program, that is focused on evaluating small molecule antagonists with dual PD-1 and T-cell immunoglobulin and mucin domain containing protein-3 (TIM-3) targeting properties.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company is also party to a collaboration with F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, under which Roche and Genentech are commercializing Erivedge® (vismodegib), a first-in-class orally-administered small molecule Hedgehog signaling pathway inhibitor, in advanced basal cell carcinoma, or BCC. Roche and Genentech are continuing to develop Erivedge in less severe forms of BCC and have communicated plans to develop Erivedge in other non-oncology indications.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company’s proprietary pipeline also includes CUDC-427, an orally-available, small molecule antagonist of inhibitor of apoptosis, or IAP proteins, and CUDC-305, a Heat Shock Protein 90, or HSP90, inhibitor. The Company currently intends to utilize its available resources for the continued development of CUDC-907 and drug candidates it licenses under the collaboration with Aurigene. As such, the Company is seeking to collaborate with third parties for the further development of CUDC-427 and CUDC-305.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company operates in a single reportable segment, which is the research and development of innovative cancer therapeutics. The Company expects that any products that are successfully developed and commercialized would be used in the health care industry and would be regulated in the United States by the Food and Drug Administration, or FDA, and in overseas markets by similar regulatory authorities.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company is subject to risks common to companies in the biotechnology industry as well as risk that are specific to the Company’s business, including, but not limited to: the Company’s ability to advance and expand its research and development programs; the Company’s reliance on Genentech and Roche to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the Company’s reliance on Aurigene to successfully discover and preclinically develop drug candidates under the parties’ collaboration agreement; the Company’s ability to obtain adequate financing to fund its operations; the ability of the Company’s wholly owned subsidiary, Curis Royalty, LLC, or Curis Royalty, to satisfy the terms of its loan agreement with BioPharma Secured Debt Fund II Sub, S.à.r.l., a Luxembourg limited liability company managed by Pharmakon Advisors, or BioPharma-II; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; dependence on key personnel; the Company’s ability to comply with regulatory requirements; and the Company’s ability to execute on its overall business strategies.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it receives and makes under its current and potential future corporate collaborations. The results of the Company’s operations may vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to: the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates; Roche and Genentech’s ability to successfully commercialize Erivedge; positive results in Roche and Genentech’s ongoing clinical trials; Aurigene’s ability to successfully discover and develop preclinical programs under the Company’s collaboration with Aurigene, as well as the Company’s decision to exclusively license and further develop programs under this collaboration; and the Company’s ability to successfully enter into one or more material outlicensing or collaboration agreements for its proprietary drug candidates.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company anticipates that existing cash, cash equivalents and investments at September 30, 2015 should enable it to maintain current and planned operations into 2017. The Company’s ability to continue funding its planned operations beyond this period is dependent upon, among other things, its ability to control expenses and its ability to raise additional funds through equity or debt financings, the success of its collaboration with Genentech, including its receipt of additional contingent cash payments under this collaboration, new collaborations or other sources of financing. The Company may not be able to successfully raise additional funds or enter into or continue any corporate collaborations and the timing, amount and likelihood of the Company receiving payments under such collaborations is highly uncertain. If the Company is unable to obtain adequate financing, the Company may be required to reduce or delay spending on its research and/or development programs.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19027935
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13678899	shares
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.70	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.94
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	0	shares
	dei	Entity Registrant Name EntityRegistrantName	CURIS INC
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0150	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.71
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.019	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.68	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	121634415	shares
	dei	Trading Symbol TradingSymbol	CRIS
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	Segment
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47985
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	95595171
	us-gaap	Net Income Loss NetIncomeLoss	-45520040
	us-gaap	Revenues Revenues	5785803
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2793096
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	338526
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2124000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-43234708
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2285332
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-118674
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	357207
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	16545
	us-gaap	Royalty Revenue RoyaltyRevenue	5997514
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-13877
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-45455529
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	154110
	us-gaap	Investment Income Interest InvestmentIncomeInterest	251692
	us-gaap	Share Based Compensation ShareBasedCompensation	2874585
CY2014Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.75
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	202542
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	348332
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9711470
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	44296
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	81000
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	26492105
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14658017
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	20911505
	us-gaap	Interest Expense InterestExpense	2537024
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-22089413
	us-gaap	Costs And Expenses CostsAndExpenses	49020511
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	62028853
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	18785
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	64619407
	us-gaap	Royalty Expense RoyaltyExpense	303209
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	75589
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	123056
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	73521081
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	24347815
	cris	Class Of Warrant Expired ClassOfWarrantExpired	1373517	shares
	cris	Royalties Terms Of Collaboration Agreement RoyaltiesTermsOfCollaborationAgreement	The term of the collaboration agreement began upon signing and, unless earlier terminated, will expire upon either (i) 90 days after the completion by Aurigene of its obligations under all research plans if the Company has not exercised the option with respect to at least one program by such time; or (ii) expiration of the last-to-expire royalty term for any and all products.
	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	Plans
	cris	Issuance Of Common Stock To Licensees IssuanceOfCommonStockToLicensees	23968183
	cris	Compensation Expenses Related To Agreement CompensationExpensesRelatedToAgreement	750000
	cris	Class Of Warrant Or Right Expiration Date ClassOfWarrantOrRightExpirationDate	2015-01-27
	cris	Research And Development Revenue Net ResearchAndDevelopmentRevenueNet	-211711
	cris	Estimated Loan Repayment Period EstimatedLoanRepaymentPeriod	2019
CY2014Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.09
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	640000	shares
CY2015Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	30000000
CY2015Q1	cris	Percentage Of Royalty On Net Sales PercentageOfRoyaltyOnNetSales	0.03	pure
CY2015Q1	cris	Non Royalty Consideration Percentage NonRoyaltyConsiderationPercentage	0.20	pure
CY2015Q1	cris	Percentage Of Royalty To Be Received PercentageOfRoyaltyToBeReceived	0.10	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	400000	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1040000	shares
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12737636	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	86004857	shares
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-5580143
CY2014Q3	us-gaap	Revenues Revenues	1764864
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4753031
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-827112
CY2014Q3	us-gaap	Royalty Revenue RoyaltyRevenue	1783271
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5584080
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	38881
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	818300
CY2014Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-67910
CY2014Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3705365
CY2014Q3	us-gaap	Interest Expense InterestExpense	933903
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	6517895
CY2014Q3	us-gaap	Royalty Expense RoyaltyExpense	89295
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	118284
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2723235
CY2014Q3	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	-37211
CY2014Q3	cris	Research And Development Revenue Net ResearchAndDevelopmentRevenueNet	-18407
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13678899	shares
CY2015Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	0	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	128392413	shares
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-5543124
CY2015Q3	us-gaap	Revenues Revenues	2044967
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4843743
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-699381
CY2015Q3	us-gaap	Royalty Revenue RoyaltyRevenue	2292608
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5488033
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	127329
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	900883
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0
CY2015Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4001069
CY2015Q3	us-gaap	Interest Expense InterestExpense	826710
CY2015Q3	us-gaap	Costs And Expenses CostsAndExpenses	6888710
CY2015Q3	us-gaap	Royalty Expense RoyaltyExpense	116145
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	106677
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2771496
CY2015Q3	cris	Adjustments To Additional Paid In Capital Share Based Compensation Mark To Market On Stock Options To Non Employees AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationMarkToMarketOnStockOptionsToNonEmployees	-93519
CY2015Q3	cris	Research And Development Revenue Net ResearchAndDevelopmentRevenueNet	-247641

Files In Submission

Name	View Source	Status
0001193125-15-371270-index-headers.html	Edgar Link	pending
0001193125-15-371270-index.html	Edgar Link	pending
0001193125-15-371270.txt	Edgar Link	pending
0001193125-15-371270-xbrl.zip	Edgar Link	pending
cris-20150930.xml	Edgar Link	completed
cris-20150930.xsd	Edgar Link	pending
cris-20150930_cal.xml	Edgar Link	unprocessable
cris-20150930_def.xml	Edgar Link	unprocessable
cris-20150930_lab.xml	Edgar Link	unprocessable
cris-20150930_pre.xml	Edgar Link	unprocessable
d14367d10q.htm	Edgar Link	pending
d14367dex311.htm	Edgar Link	pending
d14367dex312.htm	Edgar Link	pending
d14367dex321.htm	Edgar Link	pending
d14367dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2015 Q4 Form 10-Q Financial Statement

#000119312515371270 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2015 Q4 Form 10-Q Financial Statement

#000119312515371270 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris